Brokerage firm Deutsche Bank Maintains its rating on Mylan NV(NASDAQ:MYL). In a research note issued to the investors, the brokerage major Lowers the price-target to $58.00 per share. The shares have been rated Buy. The rating by Deutsche Bank was issued on Sep 23, 2016.
In a different note, On Aug 15, 2016, Leerink Swann said it Maintains its rating on Mylan NV. In the research note, the firm Raises the price-target to $51.00 per share. The shares have been rated ‘Outperform’ by the firm.
Mylan NV (MYL) made into the market gainers list on Tuesdays trading session with the shares advancing 0.32% or 0.13 points. Due to strong positive momentum, the stock ended at $41.31, which is also near the day’s high of $41.43. The stock began the session at $41.04 and the volume stood at 55,47,824 shares. The 52-week high of the shares is $55.505 and the 52 week low is $37.59. The company has a current market capitalization of $22,097 M and it has 53,49,11,500 shares in outstanding.
Mylan NV(MYL) last announced its earnings results on Aug 9, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $2.56B. Analysts had an estimated revenue of $2.57B. Earnings per share were $1.16. Analysts had estimated an EPS of $1.14.
Several Insider Transactions has been reported to the SEC. On Aug 11, 2016, Heather M Bresch (Chief Executive Officer) sold 100,200 shares at $50.00 per share price.Also, On Jun 6, 2016, Joseph C Md Maroon (director) purchased 1,670 shares at $44.95 per share price.On May 25, 2016, Robert J Cindrich (director) purchased 1,190 shares at $42.47 per share price, according to the Form-4 filing with the securities and exchange commission.
Mylan N.V. formerly Mylan Inc. is a global pharmaceutical company which develops licenses manufactures markets and distributes generic branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively North America); Europe the Middle East and Africa (collectively EMEA); and India Australia Japan and New Zealand (collectively Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India) which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.